Combination chemotherapy with 5-fluorouracil, methotrexate and etoposide for patients with high-risk gestational trophoblastic tumors: A report based on our 11-year clinical experiences

摘要: Abstract Objectives. To evaluate the efficacy, toxicity, and survival of patients with high-risk gestational trophoblastic tumors (GTTs) treated 5-fluorouracil (5-FU), methotrexate (MTX) etoposide (VP-16) regimen. Methods. Between 1992 2003, 26 consecutive FIGO-defined GTTs were 5-FU, MTX VP-16 Among them, 9 had received prior chemotherapy. Remission rate, causes treatment failure, toxicity analyzed retrospectively. Results. After regimen, 21 gained complete respond (80.8%). Two performed adjuvant hysterectomy both cured ultimately. Five developed resistance (19.2%), 1 died widespread metastases (3.8%). All 5 who multidrug regimen etoposide, methotrexate, actionmycin D alternating cyclophosphamide vincristine (the EMA/CO); 4 salvaged refractory disease. No ones relapsed. WHO grade leukocytopenia thrombocytopenia occurred in 9.0% 2.4%, respectively, total 167 cycles; other toxic effects acceptable manageable. With mean follow up 37 months, neither relapse nor secondary tumor was observed. Conclusions. According to our 11 years clinical observation, chemotherapy is one effective multiagent for GTTs. Its mild For GTTs, this new triple salvage may be an alternative.